tesaglitazar has been researched along with 3,3',5-triiodothyroacetic acid in 1 studies
Studies (tesaglitazar) | Trials (tesaglitazar) | Recent Studies (post-2010) (tesaglitazar) | Studies (3,3',5-triiodothyroacetic acid) | Trials (3,3',5-triiodothyroacetic acid) | Recent Studies (post-2010) (3,3',5-triiodothyroacetic acid) |
---|---|---|---|---|---|
74 | 13 | 25 | 255 | 11 | 47 |
Protein | Taxonomy | tesaglitazar (IC50) | 3,3',5-triiodothyroacetic acid (IC50) |
---|---|---|---|
Thyroid hormone receptor alpha | Homo sapiens (human) | 0.0001 | |
Thyroid hormone receptor beta | Rattus norvegicus (Norway rat) | 0.0002 | |
Sodium/bile acid cotransporter | Homo sapiens (human) | 6.9 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Ferrara, SJ; Scanlan, TS | 1 |
1 other study(ies) available for tesaglitazar and 3,3',5-triiodothyroacetic acid
Article | Year |
---|---|
A CNS-Targeting Prodrug Strategy for Nuclear Receptor Modulators.
Topics: Amides; Amidohydrolases; Animals; Blood-Brain Barrier; Brain; Diffusion; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Prodrugs; Receptors, Cytoplasmic and Nuclear; Tissue Distribution | 2020 |